Let's talk penny stocks. We've all played with them at one time or another, buying shares of a company trading at $1.00 or less because the stock was cheap.
Maybe you read online that a penny stock's price was likely to skyrocket because some big piece of news is going to be announced soon. Maybe your golfing buddy told you to checkout a penny stock and get in before it's too late.
Sometimes penny stock trades work out great and you can book a quick win, but often times the share price stays flat (or even goes down) and the whole trade was a giant waste of time and money.
Trading penny stocks can often feel like gambling, because you're putting up a small amount of money hoping for a big win. You can also lose all your money when you make the wrong bet.
But what if you could take the guess work out of trading penny stocks? Well, there might be a way to do that. We've gathered analyst research reports from every Wall Street firm on every public company whose shares are trading for under $1.00. There are literally thousands of these reports.
Our team sifted through them and found the ten penny stocks that Wall Street's top analysts are nearly universally bullish about. They believe these companies will have incredible upside in the next twelve months.
#1 - Sunnova Energy International (NYSE:NOVA)
- Upgrades from Top-Ranked Analysts
- 12 (in the last 90 days)
- Consensus Rating
- Hold
- Rating Score
- 2.1
- Ratings Breakdown
- 4 Buy Ratings, 23 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $5.37 (3,003.8% Upside)
About Sunnova Energy International
Sunnova Energy International Inc engages in the provision of energy as a service in the United States. The company offers electricity, as well as offers operations and maintenance, monitoring, repairs and replacements, equipment upgrades, on-site power optimization, and solar energy system and energy storage system diagnostics services.
More about Sunnova Energy International
Recent Analyst Ratings
#2 - Tempur Sealy International (NYSE:TPX)
- Upgrades from Top-Ranked Analysts
- 7 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.1
- Ratings Breakdown
- 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $72.43
About Tempur Sealy International
Tempur Sealy International, Inc, together with its subsidiaries, designs, manufactures, distributes, and retails bedding products in the United States and internationally. It provides mattresses, foundations and adjustable foundations, and adjustable bases, as well as other products comprising pillows, mattress covers, sheets, cushions, and various other accessories and comfort products under the Tempur-Pedic, Sealy, Stearns & Foster, Sealy, and Cocoon by Sealy brand names.
More about Tempur Sealy International
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 6 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.3
- Ratings Breakdown
- 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $12.90 (1,455.2% Upside)
About GeoVax Labs
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
More about GeoVax Labs
Recent Analyst Ratings
#4 - CytomX Therapeutics (NASDAQ:CTMX)
- Upgrades from Top-Ranked Analysts
- 5 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.5
- Ratings Breakdown
- 3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $4.77 (627.5% Upside)
About CytomX Therapeutics
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
More about CytomX Therapeutics
Recent Analyst Ratings
#5 - Nektar Therapeutics (NASDAQ:NKTR)
- Upgrades from Top-Ranked Analysts
- 5 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $4.50 (607.1% Upside)
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
More about Nektar Therapeutics
Recent Analyst Ratings
#6 - Quince Therapeutics (NASDAQ:QNCX)
- Upgrades from Top-Ranked Analysts
- 5 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.3
- Ratings Breakdown
- 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $8.00 (707.7% Upside)
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
More about Quince Therapeutics
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 5 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.4
- Ratings Breakdown
- 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $5.11 (738.1% Upside)
About Stardust Power
Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 5 (in the last 90 days)
- Consensus Rating
- Hold
- Rating Score
- 2.1
- Ratings Breakdown
- 2 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $3.19 (339.3% Upside)
About TPI Composites
TPI Composites, Inc manufactures and sells composite wind blades, and related precision molding and assembly systems to original equipment manufacturers (OEMs) in the United States, Mexico, Europe, the Middle East, Africa, and India. It also provides composite solutions for the automotive industry; and field service inspection and repair services comprising diagnostic, repair, and maintenance services for wind blades to OEM customers, and wind farm owners and operators.
More about TPI Composites
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 4 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.8
- Ratings Breakdown
- 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $3.88 (456.1% Upside)
About Canaan
Canaan Inc engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts.
More about Canaan
Recent Analyst Ratings
#10 - Cognition Therapeutics (NASDAQ:CGTX)
- Upgrades from Top-Ranked Analysts
- 4 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $7.13 (1,813.3% Upside)
About Cognition Therapeutics
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
More about Cognition Therapeutics
Recent Analyst Ratings
While no one can say for sure that these will be the ten best penny stocks next year, Wall Street's top analysts are giving them high price targets, "buy" ratings and are telling their clients to acquire shares.
More Investing Slideshows:
